Results 61 to 70 of about 2,313 (149)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics

Frontiers in Immunology, 2017
Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal target recognition module of a conventional antibody is composed of two non-
Peter Bannas, Julia Hambach, Friedrich Koch-Nolte   +2 more
doaj   +1 more source

Trispecific SEED antibodies engineered for neutrophil-mediated cell killing

mAbs
Immunoglobulin (Ig) A has attracted interest as a proposed therapeutic agent due to its ability to engage cell groups differently compared to an IgG scaffold and elicit tumor eradication.
Veronica Natale, Gergely Heves, Katharina Stadlbauer, Florian Rüker, Vanessa Siegmund, Lukas Pekar, Stefan Zielonka, Lars Toleikis, Stefan Becker, Gordana Wozniak-Knopp   +9 more
doaj   +1 more source

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer

Antibodies, 2019
In the last decade, cancer immunotherapies have produced impressive therapeutic results. However, the potency of immunotherapy is tightly linked to immune cell infiltration within the tumor and varies from patient to patient.
Timothée Chanier, Patrick Chames
doaj   +1 more source

Antibody engineering for SFTS treatment: frontier progress and translational challenges

Frontiers in Microbiology
Severe Fever with Thrombocytopenia Syndrome (SFTS), a highly fatal tick-borne infectious disease caused by SFTS virus (SFTSV), currently lacks globally approved specific antiviral drugs or vaccines, although favipiravir was approved in Japan for SFTS ...
Xinhan Yu, Youwang Li, Shuchen Chang, Sha Li, Huaying Huang   +4 more
doaj   +1 more source

Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L

mAbs
Multispecific antibodies (msAbs) are becoming more prevalent as formats of choice for therapeutic antibody development due to their ability to modulate multiple biological targets.
Kalie Mix, Tingwan Sun, Brian Hall, Jocelyn Newton, Christina Eng, Yongjing Guo, David Reczek   +6 more
doaj   +1 more source

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma

HemaSphere, Volume 10, Issue 6, June 2026.
Gala Vega, Daniel Morillo, Christine Riedhammer, Febe Smits, Aishee Bag, Kelly Julian, Natalia Tovar Gomis, Carmen Montes Gaisan, Maria Aranzazu Bermudez, Mansi R. Shah, Ghulam Rehman Mohyuddin, Binod Dhakal, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Niels W. C. J. van de Donk, Rajshekhar Chakraborty, Meera Mohan   +18 more
wiley   +1 more source

Single-domain antibodies as therapeutics for solid tumor treatment

Acta Pharmaceutica Sinica B
Single-domain antibodies (sdAbs), initially identified in camelids or sharks and commonly referred to as nanobodies or VNARs, have emerged as a promising alternative to conventional therapeutic antibodies.
Mingkai Wang, Tianlei Ying, Yanling Wu
doaj   +1 more source

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies

mAbs
Immunogenicity prediction is widely used in the developability assessment of antibodies, and many marketed and clinical-stage therapeutics have a predicted T-cell epitope in the second complementary-determining region of their light chain (CDR2L).
Maria U. Johansson, Anne Kerschenmeyer, Alessandra Carella, Simon Carnal, Yannik Schmidt, Alessandra de Felice, Dana Mahler, Marc Thomas, Fabio Mario Spiga, Julia Tietz, Christopher Weinert, Christian Hess, David Urech, Stefan Warmuth   +13 more
doaj   +1 more source

Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies. [PDF]

Biol Chem, 2022
Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K, Forster M, Wessels U, Stubenrauch KG, Benz J, Ehler A, Lauer ME, Ringler P, Kobold S, Endres S, Klein C, Brinkmann U.   +16 more
europepmc   +1 more source

Antibodies and cryptographic hash functions: quantifying the specificity paradox

Frontiers in Immunology
The specificity of the immune response is critical to its biological function, yet the generality of immune recognition implies that antibody binding is multispecific or degenerate.
Robert J. Petrella, Robert J. Petrella
doaj   +1 more source